GILD Wins Approval for Twice-Yearly HIV Prevention Shot in the EU

Gilead Sciences (GILD) has secured EU marketing authorization for lenacapavir (Yeytuo), its twice-yearly injectable HIV prevention drug, bolstering its HIV portfolio amidst generic competition for Truvada. This approval, supported by robust Phase III trial data, positions Yeytuo as a significant long-acting PrEP option, contributing to GILD's 23.5% year-to-date share surge. However, the drug faces commercial hurdles, notably CVS Health's decision to exclude Yeztugo (U.S. brand) from its commercial plans due to cost and other factors, despite ongoing negotiations.

Analysis

Gilead Sciences (GILD) has secured a significant regulatory victory with the European Commission's approval of its twice-yearly HIV prevention injectable, lenacapavir (Yeytuo), reinforcing its dominant HIV franchise. This approval, which followed an accelerated review and grants an additional year of market protection in the EU, is supported by robust late-stage trial data from the PURPOSE 1 and 2 studies, demonstrating superiority over the daily oral pill Truvada. The less frequent dosing schedule provides a distinct competitive advantage over both daily PrEP options and GSK's bi-monthly injectable, Apretude, potentially addressing key barriers to patient adherence. This positive development contributes to the stock's 23.5% year-to-date surge, which significantly outpaces the industry's 2.2% growth. However, a critical headwind has emerged in the U.S. market, where pharmacy benefit manager CVS Health has initially declined to add the drug (branded Yeztugo) to its commercial formularies, citing clinical and financial factors, including its high list price of over $28,000 per year. This decision introduces substantial uncertainty regarding the drug's commercial uptake and revenue trajectory in its largest potential market, tempering the otherwise positive outlook from the recent regulatory approvals.

Key Decisions for Investors

• The EU approval and superior clinical profile of lenacapavir bolster Gilead's long-term outlook in the HIV market, suggesting investors should view this as a key asset to offset generic erosion of Truvada.
• Investors must closely monitor the outcomes of negotiations with U.S. pharmacy benefit managers like CVS, as formulary inclusion is a critical catalyst for revenue realization and will heavily influence the stock's near-term performance.
• Consider the competitive landscape, particularly the market uptake of GSK's Apretude, to assess the pace and ceiling of lenacapavir's market share capture in the long-acting PrEP segment.
• Given the stock's significant 23.5% year-to-date run-up, the uncertainty around U.S. market access may present a near-term risk, warranting a cautious approach until coverage decisions become clearer.